Prognostic impact of BCL2, BCL6 and MYC status in de novo diffuse large B-cell lymphoma: a regional study of 43 patients
Loading...
Date
2019-05
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with marked biologic heterogeneity. We aimed to evaluate the status of MYC, BCL2, BCL6 in patients with DLBCL.Methods: Herein, we have investigated the prognostic relevance of MYC, BCL2 and BCL6 from 43 de novo DLBCL patients.Results: In this study, protein overexpression of BCL2 and BCL6 was encountered in 46.5% (n=20) and 27.9% (n=12) of the tumors, respectively. Rearrangements in MYC, BCL6, and BCL2 were detected in 9.3% (n=4), 25.6% (n=11), and 4.7% (n=2) of the cases, respectively. Any statistically significant difference could not be found between Bcl-2, Bcl-6 expression, C-MYC rearrangement and the survival.Conclusions: We concluded that C-MYC and BCL2 may contribute to aggressive transformation, so more mechanism-based therapy should be explored. A larger study is warranted to better understand the immunophenotypic and molecular features of DLBCL and their respective impact on patient survival.
Description
Keywords
Diffuse large B-cell lymphoma, Fluorescence in situ hybridization, Immunohistochemistry, Prognosis, MYC, BCL6, BCL2
Citation
Kahraman Dudu Solakoglu, Diniz Gulden, Ceylan Cengiz, Ozalp Faruk Recep, Koca Yetkin, Ekmekci Sumeyye, Ayaz Duygu, Sayhan Sevil. Prognostic impact of BCL2, BCL6 and MYC status in de novo diffuse large B-cell lymphoma: a regional study of 43 patients. International Journal of Research in Medical Sciences. 2019 May; 7(5): 1720-1726